 This study is to evaluate the safety of 3.0 gday of SA-001 to be flexibly increased or decreased with the range from 1.5 gday to 6.0 gday, which will orally be administered for 52 weeks to patients with pancreatic exocrine insufficiency caused by chronic pancreatitis in the non-compensatory stage or by pancreatectomy. 